A Phase 3, Open Label, Multi-Center, Extension Study to Assess Antibody Persistence and Response to a Third or Fifth Dose of Novartis Meningococcal B Recombinant Vaccine in 4-Year-Old Children Who Previously Participated in Study V72P12E1
Phase of Trial: Phase III
Latest Information Update: 30 Nov 2016
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary)
- Indications Meningococcal group B infections
- Focus Pharmacodynamics
- Sponsors Novartis Vaccines
- 30 Nov 2016 Results assessing immunity to vaccine antigens published in the Vaccine.
- 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2013 Planned End Date changed from 1 Jan 2014 to 1 Nov 2013 as reported by ClinicalTrials.gov.